Jurata's proprietary thin films (shown above) stabilizes the three-dimensional structure of biologic materials in a thermostable film matrix, removing cold chain logistics in pharmaceutical fill/finish, distribution, storage, and delivery. Our thin film has been validated with many active pharmaceutical ingredients (API), stabilizing biologics for three years at room temperature (25°C), as well as protecting embedded API at temperatures as low as -80°C and as high as 60°C.
Due to the lightweight, compact, and temperature stability of our thin films, this technology would greatly reduce the need for specialized resources and simplify the logistics for transport, distribution, and storage of vaccines and biologics by completely eliminating the need for cold chain logistics. The thermostable nature of our thin films enable them to maintain the therapeutic efficacy of its payload, even at extreme temperatures.
While current pharmaceutical fill/finish processes require extremely low temperatures, incredibly large energy consumption, and can take up to 85 hours per cycle, Jurata's process takes place at room temperature and requires only 3 hours to complete. This process could be readily adapted for low- and middle-income countries, as well as low-resource regions in developed nations.
Jurata's thin film technology has been validated with:
· Live Recombinant Adenovirus
· Live Influenza
- mRNA LNPs
- Antibodies
· Live E coli
· Plasmid DNA
· Antibody-Enzyme Conjugates
· Adjuvants
· …and more
Our thin film technology can even be used to directly deliver vaccines and therapeutic payloads through buccal (inside the cheek) or sublingual (under the tongue) routes. Alternatively, our films can be rehydrated to recover the therapeutic payload in an aqueous solution, which can then be administered via intranasal or parenteral routes. These routes of administration can improve the potency of biologics without using needles, for wholly non-invasive vaccine and drug delivery. We are also optimizing the MSI-TX thin film for rapid and/or continuous release of therapeutic payloads, further increasing its potential applications in the clinic.
If you would like to discuss any of our results or are interested in studying our thin film technology for your company's therapeutics, please contact us using the link below.
Molecular Pharmaceutics (2015)
Science Advances (2020)
Journal of Controlled Release (2022)
Nature Communications Medicine (2022)
If you are interested in learning more about the MSI-TX thin film or becoming our partner, please contact us using the link below.
Jurata Thin Film, Inc.
Houston, Texas, USA
Copyright © 2024 Jurata Thin Film - All Rights Reserved.